- Home
- KNDI vs CRBP Comparison
KNDI vs CRBP Comparison
Compare KNDI & CRBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KNDI
- CRBP
- Stock Information
- Founded
- KNDI 2002
- CRBP 2009
- Country
- KNDI China
- CRBP United States
- Employees
- KNDI N/A
- CRBP N/A
- Industry
- KNDI Auto Manufacturing
- CRBP Biotechnology: Pharmaceutical Preparations
- Sector
- KNDI Consumer Discretionary
- CRBP Health Care
- Exchange
- KNDI Nasdaq
- CRBP Nasdaq
- Market Cap
- KNDI 109.2M
- CRBP 114.8M
- IPO Year
- KNDI N/A
- CRBP N/A
- Fundamental
- Price
- KNDI $1.38
- CRBP $11.62
- Analyst Decision
- KNDI
- CRBP Strong Buy
- Analyst Count
- KNDI 0
- CRBP 11
- Target Price
- KNDI N/A
- CRBP $51.90
- AVG Volume (30 Days)
- KNDI 138.6K
- CRBP 125.6K
- Earning Date
- KNDI 11-17-2025
- CRBP 11-06-2025
- Dividend Yield
- KNDI N/A
- CRBP N/A
- EPS Growth
- KNDI N/A
- CRBP N/A
- EPS
- KNDI N/A
- CRBP N/A
- Revenue
- KNDI $104,035,613.00
- CRBP N/A
- Revenue This Year
- KNDI N/A
- CRBP N/A
- Revenue Next Year
- KNDI N/A
- CRBP $220.00
- P/E Ratio
- KNDI N/A
- CRBP N/A
- Revenue Growth
- KNDI N/A
- CRBP N/A
- 52 Week Low
- KNDI $0.89
- CRBP $4.64
- 52 Week High
- KNDI $2.07
- CRBP $53.23
- Technical
- Relative Strength Index (RSI)
- KNDI 49.94
- CRBP 71.90
- Support Level
- KNDI $1.34
- CRBP $9.06
- Resistance Level
- KNDI $1.45
- CRBP $9.73
- Average True Range (ATR)
- KNDI 0.07
- CRBP 0.67
- MACD
- KNDI -0.02
- CRBP 0.15
- Stochastic Oscillator
- KNDI 19.05
- CRBP 82.61
About KNDI Kandi Technologies Group Inc
Kandi Technologies Group Inc is engaged in developing, manufacturing, and commercializing fully electric vehicle products and related technologies. Its products mainly consist of EV parts, EV products, and off-road vehicles, including All-Terrain Vehicles (ATVs), UTVs, go-karts, electric scooters, electric self-balancing scooters, and associated parts, and Lithium-ion cells, etc. The company generates maximum revenue from the sale of Off-road vehicles and associated parts. Geographically, it derives maximum revenue from the United States and other countries, followed by China.
About CRBP Corbus Pharmaceuticals Holdings Inc.
Corbus Pharmaceuticals Holdings Inc is a precision oncology company with a diversified portfolio and is committed to helping people defeat serious illness by bringing scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.